Exact Sciences (EXAS) Financial Analysis & Valuation | Quarter Chart
Exact Sciences (EXAS)
EXASPrice: $104.91
Fair Value: 🔒
🔒score
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also pr... more
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United Stat... more
Description
Shares
| Market Cap | $20.03B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Kevin T. Conroy |
| IPO Date | 2001-02-01 | CAGR | — |
| Employees | 6,900 | Website | www.exactsciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
EXAS chart loading...
Fundamentals
Technicals
| Enterprise Value | $20.84B | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 6.17 | P/B Ratio | 8.29 |
| P/CF Ratio | 40.5 | P/FCF Ratio | 56.13 |
| EPS | $-1.1 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 17.69% | Gross Margin | 0.7% |
| Operating Margin | -0.06% | Profit Margin | -0.06% |
| ROE | -0.09% | ROA | -0.04% |
| ROCE | -0.04% | Current Ratio | 2.23 |
| Quick Ratio | 1.97 | Cash Ratio | 1.49 |
| Debt/Equity | 1.05 | Interest Coverage | -5.47 |
| Altman Z Score | 2.96 | Piotroski Score | 5 |